Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
March 28, 2022 07:13 AM EDT
FDA+

Paul Hud­son's rare dis­ease piv­ot takes a small step for­ward, as Nie­mann-Pick drug wins Japan ap­proval

Max Gelman

Senior Editor

As Sanofi CEO, Paul Hud­son has made no se­cret of his de­sire to de­vel­op new break­through drugs and broad­en his com­pa­ny’s of­fer­ings. That ef­fort inched …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times